文献速递消化系统肿瘤

S-1联合伊立替康及贝伐珠单抗一线治疗转移性结直肠癌的非劣效III期研究

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
PubMed 文献 · Ann Oncol · 2018-01-01

TRICOLORE研究为随机、开放标签、III期非劣效试验,纳入487例初治转移性结直肠癌患者,比较S-1联合伊立替康及贝伐珠单抗与mFOLFOX6或CapeOX联合贝伐珠单抗的疗效。主要终点无进展生存期(PFS)显示试验组非劣于对照组(HR 0.84,95%CI 0.70-1.02,非劣效P<0.0001)。

要点

  • S-1联合伊立替康及贝伐珠单抗一线治疗mCRC的PFS非劣于mFOLFOX6/CapeOX联合贝伐珠单抗。
  • 试验组中位PFS为14.0个月,对照组为10.8个月(HR 0.84,95%CI 0.70-1.02)。
  • 试验组≥3级不良事件发生率为58.6%,对照组为64.9%。

核心结论

  • S-1联合伊立替康及贝伐珠单抗一线治疗mCRC的PFS非劣于mFOLFOX6或CapeOX联合贝伐珠单抗,可能成为新的标准治疗。

研究设计与样本

  • 随机、开放标签、III期非劣效试验,来自53家机构,共随机分配487例初治mCRC患者(1:1)。
  • 对照组接受mFOLFOX6或CapeOX联合贝伐珠单抗;试验组接受S-1联合伊立替康及贝伐珠单抗(3周或4周方案)。
  • 主要终点为PFS,非劣效界值为1.25(对照组与试验组HR的95%CI上限小于该值即判定非劣效)。

主要发现

  • 对照组中位PFS为10.8个月(95%CI 9.6-11.6),试验组为14.0个月(95%CI 12.4-15.5)。
  • HR为0.84(95%CI 0.70-1.02);非劣效P<0.0001,优效性P=0.0815。

关键数值与推荐

  • 非劣效界值为1.25,HR的95%CI上限为1.02,小于界值,非劣效成立。

临床怎么用

  • 对于初治mCRC患者,可考虑S-1联合伊立替康及贝伐珠单抗作为一线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC). We carried out a randomized, open-label, phase III trial to determine whether S-1 and irinotecan plus bevacizumab is noninferior to mFOLFOX6 or CapeOX plus bevacizumab in terms of progression-free survival (PFS). PATIENTS AND METHODS: Patients from 53 institutions who had previously untreated mCRC were randomly assigned (1 : 1) to receive either mFOLFOX6 or CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group; a 3-week regimen: intravenous infusions of irinotecan 150 mg/m2 and bevacizumab 7.5 mg/kg on day 1, oral S-1 80 mg/m2 twice daily for 2 weeks, followed by a 1-week rest; or a 4-week regimen: irinotecan 100 mg/m2 and bevacizumab 5 mg/kg on days 1 and 15, S-1 80 mg/m2 twice daily for 2 weeks, followed by a 2-week rest). The primary end point was PFS. The noninferiority margin was 1.25; noninferiority would be established if the upper limit of the 95% confidence interval (CI) for the hazard ratio (HR) of the control group versus the experimental group was less than this margin. RESULT: Between June 2012 and September 2014, 487 patients underwent randomization. Two hundred and forty-three patients assigned to the control group and 241 assigned to the experimental group were included in the primary analysis. Median PFS was 10.8 months (95% CI 9.6-11.6) in the control group and 14.0 months (95% CI 12.4-15.5) in the experimental group (HR 0.84, 95% CI 0.70-1.02; P < 0.0001 for noninferiority, P = 0.0815 for superiority). One hundred and fifty-seven patients (64.9%) in the control group and 140 (58.6%) in the experimental group had adverse events of grade 3 or higher. CONCLUSION: S-1 and irinotecan plus bevacizumab is noninferior to mFOLFOX6 or CapeOX plus bevacizumab with respect to PFS as first-line treatment of mCRC and could be a new standard treatment. CLINICAL TRIALS NUMBER: UMIN000007834.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Yamada Y, Denda T, Gamoh M, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol. 2018. PMID: 29293874. doi:10.1093/annonc/mdx816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。